139563-25-0

Basic information

• Product Name: (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-1H-4,7-methanisoindol-1,3-dione dihydrochloride
• CAS NO: 139563-25-0
• Molecular Weight: 565.607
• Mol File: 139563-25-0.mol
• Article Data: 21

Chemical Properties

• CAS DataBase Reference: (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-1H-4,7-methanisoindol-1,3-dione dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-1H-4,7-methanisoindol-1,3-dione dihydrochloride(139563-25-0)
• EPA Substance Registry System: (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-1H-4,7-methanisoindol-1,3-dione dihydrochloride(139563-25-0)

Safety Data

• Hazardous Substances Data: 139563-25-0(Hazardous Substances Data)

Usage

Description

(3aR,4S,7R,7aS)-2-(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethylhexahydro-1H-4,7-methanisoindol-1,3-dione dihydrochloride is a complex organic compound with a specific stereochemistry and structure. It is characterized by its unique arrangement of atoms and functional groups, which may contribute to its potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
(3aR,4S,7R,7aS)-2-(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethylhexahydro-1H-4,7-methanisoindol-1,3-dione dihydrochloride is used as an active pharmaceutical ingredient for the treatment of various medical conditions. Its specific structure and stereochemistry may provide unique therapeutic properties, making it a valuable compound for drug development and formulation.
Used in Research and Development:
(3aR,4S,7R,7aS)-2-(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethylhexahydro-1H-4,7-methanisoindol-1,3-dione dihydrochloride is also used in research and development settings to study its chemical properties, interactions with biological systems, and potential applications in drug discovery. Its complex structure and stereochemistry make it an interesting subject for scientific investigation and may lead to the development of new therapeutic strategies.
Used in Impurity Analysis:
As an impurity of the drug Lurasidone (L474920), an antipsychotic used for the treatment of schizophrenia, (3aR,4S,7R,7aS)-2-(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethylhexahydro-1H-4,7-methanisoindol-1,3-dione dihydrochloride is used in the analysis and quality control of Lurasidone to ensure the safety and efficacy of the drug. Monitoring and controlling impurities is crucial in the pharmaceutical industry to maintain the desired therapeutic effects and minimize potential side effects.

Upstream product

• 194861-74-0 lurasidone 
• 367514-88-3 (3aR,4S,7R,7aS)-2-[((1R,2R)-2-{[4-(l1,2-benzisothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl)methyl]hexahydro-1H-4,7-methanisoindol-1,3-dione hydrochloride 
• 65376-05-8 (+)-(1R,2R)-trans-1,2-bis(hydroxymethyl)cyclohexane 
• 139563-20-5 (3aR,4S,7R,7aS)-2-(((1R,2R)-2-((4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)cyclohexyl)methyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione tartrate 
• 186204-37-5 (3aR,7aR)-4’-(benzo[d]isothiazol-3-yl)octahydrospiro[isoindole-2,1’-piperazin]-2-ium methanesulfonate 
• 87691-87-0 3-(1-piperazinyl)-1,2-benzisothiazole 
• 194861-74-0 [14C]-Lurasidone 
• 133070-64-1 3-(piperazin-1-yl)-1,2-benzisothiazole hydrochloride 
• 46022-05-3 (1R,2R)-(-)-trans-cyclohexane-1,2-dicarboxylic acid 
• 140459-96-7 (1R,2R)-1,2-cyclohexanedicarboxylic acid dimethyl ester 
• 7647-01-0 hydrogenchloride 
• 129-64-6 3,6-endomethylene-1,2,3,6-tetrahydrophthalic anhydride 
• 14805-29-9 (3aR,4S,7R,7aS)?4,7?methylene?1H?isoindole?1,3(2H)-dione 

Relevant articles and documents

Method for preparing lurasidone and salt thereof

The invention relates to a method for preparing lurasidone and a salt thereof. The method comprises the following steps: reacting (R,R)-1,2-bis(methanesulfonyloxymethyl)cyclohexane and 3-(1-piperazinyl)-1,2-benzoisothiazole hydrochloride in acetonitrile in the presence of potassium carbonate to obtain an intermediate I; reacting the intermediate I with (3aR,4S,7R,7aS)-4,7-methylene-1H-isoindole-1,3(2H)-dione in DMF in the presence of potassium carbonate to prepare lurasidone free alkali; and reacting the lurasidone free alkali with hydrochloric acid in isopropanol to obtain lurasidone hydrochloride. The invention also relates to lurasidone and the salt thereof prepared by using the method, and application of lurasidone and the salt thereof in medicines for resisting psychosis, especially schizophrenia. The method disclosed by the invention has one or more advantages in a group consisting of simple process, high product yield, few impurities and the like.

Lurasidone key intermediate preparation method

The present invention relates to a lurasidone key intermediate preparation method, and belongs to the technical field of compound synthesis. According to the method, when 4,-(1,2-benzisothiazol-3-yl)-(3aR,7aR)-octahydrospiro(2H-isoindole-2,1-piperazine)methanesulfonate is generated, 4-(1,2-benzisothiazol-3-yl)-1-piperazine is adopted as a raw material, the 4-(1,2-benzisothiazol-3-yl)-1-piperazine, (1R,2R)-1,2-bis(methanesulfonyloxymethyl)cyclohexane and potassium carbonate are subjected to a reaction in a solvent toluene, and a cyclodextrin phase transfer catalyst is added to the reaction system. According to the present invention, by using the cyclodextrin as the phase transfer catalyst, the incomplete reaction problem is solved, and the yield is substantially improved.

A method for preparing [...]

The invention provides a method for preparing lurasidone. The preparation method comprises reacting 1-(1,2-benzisothiazol-3-yl) piperazine with (R, R)-1,2-bis(methylsulfonyl-methoxy) cyclohexane in a mixed solvent of acetonitrile/water in presence of bicarbonate as a base, adding toluene or xylene, separating an organic layer out, adding bicyclo [2.2.1] heptane-2,3-dicarboximide and carbonate into the organic layer and reacting to obtain lurasidone. The conventional separation and purification steps are omitted and the cost of production is greatly reduced; at the same time, the method has the characteristics of high yield and high purity of the product.